Clinical trials
Phase 2 Coronary Artery Disease trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
88 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 4 |
| 2009 | 7 |
| 2010 | 1 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 9 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
| Terminated | 7 |
| Recruiting | 4 |
| Unknown status | 4 |
| Withdrawn | 3 |
| Not yet recruiting | 3 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 11 |
| Eli Lilly and Company | 4 |
| Indiana University | 3 |
| Johns Hopkins University | 3 |
| The Medicines Company | 3 |
| Anthera Pharmaceuticals | 2 |
| AstraZeneca | 2 |
| Cell>Point LLC | 2 |
| Cytori Therapeutics | 2 |
| Emory University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronary Artery Disease | 88 |
| Coronary Disease | 14 |
| Myocardial Ischemia | 13 |
| Atherosclerosis | 12 |
| Cardiovascular Diseases | 12 |
| Heart Diseases | 10 |
| Ischemia | 6 |
| Acute Coronary Syndrome | 4 |
| Heart Valve Diseases | 4 |
| Inflammation | 4 |
Trials
Showing 1 to 25 of 88. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.